Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S. and internationally. It will report its Q1 2025 earnings on April 29.

Pfizer Inc. (PFE) is a multinational pharmaceutical and biotechnology company headquartered in New York. It researches, develops, and manufactures biopharmaceutical products for use in the ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other Jeff Smith’s top activist targets. Jeff Smith is arguably the “most feared man” in corporate ...

Pfizer decided to discontinue the development of its leading weight management candidate. Despite this setback, the company has a deep pipeline of candidates, especially in oncology. Pfizer's ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

The reversal from the Advisory Committee on Immunization Practices (ACIP) is a potential boost for GSK and Pfizer. Both companies saw sales of their RSV vaccines for adults tumble last year after ...

Dr Chris Boshoff, Pfizer's Chief Scientific Officer, confirmed in statement on April 14: 'While we are disappointed to discontinue the development of danuglipron, we remain committed to ...

open image in gallery Drugmaker Pfizer announced its decision to discontinue the development of its potential once-daily pill treatment for obesity, known as danuglipron. The decision came after a ...

Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial experienced a potentially drug-related liver injury. The drugmaker Pfizer is ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...

Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury. The company said the injury went away after the person ...